Conventional Industrial Robotics Applied to the Process of Tomato Grafting Using the Splicing Technique

Horticultural grafting is routinely performed manually, demanding a high degree of concentration and requiring operators to withstand extreme humidity and temperature conditions. This article presents the results derived from adapting the splicing technique for tomato grafting, characterized by the coordinated work of two conventional anthropomorphic industrial robots with the support of low-cost passive auxiliary units for the transportation, handling, and conditioning of the seedlings. This work provides a new approach to improve the efficiency of tomato grafting. Six test rates were analyzed, which allowed the system to be evaluated across 900 grafted units, with gradual increases in the speed of robots work, operating from 80 grafts/hour to over 300 grafts/hour. The results obtained show that a higher number of grafts per hour than the number manually performed by skilled workers could be reached easily, with success rates of approximately 90% for working speeds around 210–240 grafts/hour

Propuesta de rehabilitación de la ex Colecturía del Diezmo para Centro Cultural en el municipio de Chalchicomula de Sesma

“Un espacio cultural es aquél que generalmente se encuentra en algún tipo de edificio que, reciclado o construido especialmente, ha sido destinado a la creación, producción, promoción y/o difusión de las artes y la cultura. Al hablar de espacios culturales en el estado de Puebla nos encontramos con una grave crisis, ya que de los 217 municipios con los que cuenta el estado, sólo 70 de estos cuentan con la infraestructura adecuada para el desarrollo de actividades culturales, es decir, más de la mitad del estado carece de espacios dignos para la práctica de estas actividades. Entre los municipios del estado que se encuentran en esta situación de carencia de espacios culturales se sitúa Chalchicomula de Sesma, ya que el lugar que fungía como Casa de Cultura tuvo un cambio de uso a Museo Regional del INAH en el año 2016, provocando la falta casi total de espacios para una correcta práctica de actividades culturales. Entre las actividades que se desarrollaban en la casa de cultura antes mencionada se impartían conferencias del INAOE, el GTM, la BUAP, la UNAM y el CONACYT, así como talleres de tejido, bordado y manualidades, entre otras”

INFLUENCIA DE LA RUGOSIDAD INICIAL EN EL COMPORTAMIENTO TRIBOLÓGICO DE UN ACERO H13 NITRURADO

Se investigó la influencia de la rugosidad superficial en el comportamiento tribológico de un acero AISI H13 nitrurado mediante ensayos de fricción en seco. Se prepararon tres diferentes rugosidades en los rangos de 0.04 a 0.41 µm. Se observó que para superficies más rugosas se obtienen volúmenes perdidos y factores de desgaste más elevados. Por otro lado, el coeficiente de fricción tuvo una tendencia a incrementar con rugosidades mayores a 0.1 µm; mientras que debajo de ese valor, los coeficientes de fricción son muy similares. El mecanismo de desgaste predominante fue abrasivo pero también se pudo observó deformación plástica y oxidación de la superficie.Palabra(s) Clave(s): Acero H13, desgaste, fricción, nitrurado, rugosidad

Seismotectonic and geologic characterization of the february 1999 Mb: 4,8 Mula earthquake using geological data, seismological data and RADAR interferometry (INSAR)

La secuencia sísmica de Mula (Murcia) iniciada el 2 de Febrero de 1999 con un terremoto máximo de Mb: 4,8 alcanzó una intensidad MSK máxima de VI-VII causando numerosos daños materiales. Los datos sismológicos existentes hasta la fecha, y concretamente la profundidad hipocentral y los mecanismos focales difieren de forma significativa en función del método de cálculo usado. En este trabajo se ha utilizado una técnica novedosa como es la interferometría de RADAR (INSAR) con el fin de identificar posibles deformaciones superficiales asociadas el terremoto que ayuden a identificar la fuente sismogenética. La combinación de los resultados obtenidos con esta técnica unidos a los datos geológicos de superficie apunta, como fuente más probable, a la reactivación de la falla de Crevillente con una componente de desgarre importante y con un epicentro somero (profundidad inferior a 10 km).The 1999 Mula (Murcia) seismic sequence started in February 2nd with a Mb: 4.8 mainshock, that reached a MSK intensity VI-VII. This earthquake produced significant economic losses in the region. The seismological data available to date give different focal mechanisms and different focal depths depending on the applied method. In this work we used a modern technique as RADAR interferometry (INSAR) with the aim to identify coseismic surface displacements linked with the Mula earthquake. The correlation of the results from RADAR interferometry with geological data support a reactivation of the Crevillente fault, with a high strike-slip component and a shallow hipocenter (less than 10 km), as the more likely seismic source.Depto. de Geodinámica, Estratigrafía y PaleontologíaFac. de Ciencias GeológicasTRUEEspaña. Comisión Interministerial de Ciencia y Tecnologíapu

Informe del sismo de Lorca del 11 de mayo de 2011

En la reciente historia sísmica de España, desde el terremoto de 1956 en Albolote (Granada) con once muertos y el de 1969 al SW del Cabo San Vicente con cuatro, el terremoto de Lorca de 11 de mayo de 2011 (magnitud 5.1) ha vuelto a ser especialmente importante por haber ocasionado nueve víctimas mortales. El movimiento sísmico, localizado muy próximo a la ciudad de Lorca, ha afectado directamente a más de 90.000 personas, que han sufrido sus consecuencias al registrarse con una intensidad de grado VII en la escala europea EMS, lo que ha motivado daños notables en las viviendas. El presente informe trata de reflejar las características del terremoto y de su serie de réplicas, recogiendo los trabajos que han desarrollado diferentes equipos de investigación, tanto previos al terremoto como posteriores. El estudio describe los aspectos científicos y técnicos de mayor interés, desde la historia sísmica de la zona hasta el comportamiento de las edificaciones de la ciudad de Lorca. Asimismo, se acompaña de un encuadre geológico de la zona y de las características de la falla de Alhama de Murcia, responsable de la ocurrencia del terremoto. Como consecuencia de los terremotos que hubo la misma zona en el año 2005, precedidos por un apreciable nivel de actividad sísmica en los años 1999 y 2002, la región de Murcia fue objeto del proyecto RISMUR, cofinanciado por el Instituto Geográfico Nacional y en el que participaron los redactores de este informe. Algunos de los aspectos de este proyecto, en concreto los relativos a la peligrosidad sísmica han sido incluidos, incidiendo en los resultados que se obtuvieron en la ciudad de Lorca. El informe va acompañado al final de una serie de conclusiones en relación con cada uno de los temas tratados, resaltando aquellos aspectos que se deberán tener en cuenta en futuros proyectos, a fin de mejorar por un lado el conocimiento de la sismicidad y peligrosidad sísmica y por otro para la adecuación de la normativa sismorresistente.Peer reviewe

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

This article belongs to the Collection The Biomarkers for the Diagnosis and Prognosis in Cancer.[Simple Summary] Mutational profiling using a custom 43-gene next-generation sequencing panel revealed that patients with mutated DNMT3A or EZH2, or an increase in TET2 VAF and lower TP53 VAF showed a higher overall response. NRAS and TP53 variants were associated with shorter overall survival (OS), whereas only mutated BCOR was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low–intermediate cytogenetic risk and mutated NRAS benefited from azacytidine therapy and patients with mutated TP53 showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML.[Abstract] We sought to predict treatment responses and outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group) based on mutational status, comparing azacytidine (AZA) with fludarabine plus low-dose cytarabine (FLUGA). Mutational profiling using a custom 43-gene next-generation sequencing panel revealed differences in profiles between older and younger patients, and several prognostic markers that were useful in young patients were ineffective in older patients. We examined the associations between variables and overall responses at the end of the third cycle. Patients with mutated DNMT3A or EZH2 were shown to benefit from azacytidine in the treatment-adjusted subgroup analysis. An analysis of the associations with tumor burden using variant allele frequency (VAF) quantification showed that a higher overall response was associated with an increase in TET2 VAF (odds ratio (OR), 1.014; p = 0.030) and lower TP53 VAF (OR, 0.981; p = 0.003). In the treatment-adjusted multivariate survival analyses, only the NRAS (hazard ratio (HR), 1.9, p = 0.005) and TP53 (HR, 2.6, p = 9.8 × 10−7) variants were associated with shorter overall survival (OS), whereas only mutated BCOR (HR, 3.6, p = 0.0003) was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low–intermediate cytogenetic risk (HR, 1.51, p = 0.045) and mutated NRAS (HR, 3.66, p = 0.047) benefited from azacytidine therapy. In the subgroup analyses, patients with mutated TP53 (HR, 4.71, p = 0.009) showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML. The study is registered at ClinicalTrials.gov as NCT02319135.This study was supported by the Centro de Investigación Biomédica en Red—Área de Oncología–del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369) and the Subdirección General de Investigación Sanitaria (Instituto de Salud Carlos III, Spain) grants PI16/01530, PI16/01661, PI19/01518, and PI19/00730, the CRIS against Cancer foundation, grant 2018/001, and by the Instituto de Investigación Hospital 12 de Octubre (IMAS12) (co-financed by FEDER funds). The study was supported internationally by Cancer Research UK, FCAECC and AIRC under the Accelerator Award Program

Efficacy, Safety and Cost-Effectiveness of Methotrexate, Adalimumab or Their Combination in Non-infectious Non-anterior Uveitis: A Protocol for a Multicentre, Randomised, Parallel Three Arms, Active-Controlled, Phase III Open Label With Blinded Outcome Assessment Study

[Abstract] Introduction: Non-infectious uveitis include a heterogeneous group of sight-threatening and incapacitating conditions. Their correct management sometimes requires the use of immunosuppressive drugs (ISDs), prescribed in monotherapy or in combination. Several observational studies showed that the use of ISDs in combination could be more effective than and as safe as their use in monotherapy. However, a direct comparison between these two treatment strategies has not been carried out yet. Methods and analysis: The Combination THerapy with mEthotrexate and adalImumAb for uveitis (CoTHEIA) study is a phase III, multicentre, prospective, randomised, single-blinded with masked outcome assessment, parallel three arms with 1:1:1 allocation, active-controlled, superiority study design, comparing the efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis. We aim to recruit 192 subjects. The duration of the treatment and follow-up will last up to 52 weeks, plus 70 days follow-up with no treatment. The complete and maintained resolution of the ocular inflammation will be assessed by masked evaluators (primary outcome). In addition to other secondary measurements of efficacy (quality of life, visual acuity and costs) and safety, we will identify subjects’ subgroups with different treatment responses by developing prediction models based on machine learning techniques using genetic and proteomic biomarkers. Ethics and dissemination: The protocol, annexes and informed consent forms were approved by the Reference Clinical Research Ethic Committee at the Hospital Clínico San Carlos (Madrid, Spain) and the Spanish Agency for Medicines and Health Products. We will elaborate a dissemination plan including production of materials adapted to several formats to communicate the clinical trial progress and findings to a broad group of stakeholders. The promoter will be the only access to the participant-level data, although it can be shared within the legal situation. Trial registration number: 2020-000130-18; NCT04798755.This work was supported by the Instituto de Salud Carlos III, grant number [ICI19/00020]. Sponsor: Fundación para la Investigacion Biomédica del Hospital Clínico San Carlos. Executive Committee: Administrative and executive arm of the clinical trial, providing overall oversight for the study and making decisions on day-to-day operational issues (Study Coordinator (Luis Rodriguez-Rodriguez), a representative from the Spanish Clinical Trial Network (Amanda López Picado), and 5 Site Directors (these seats will be rotatory, with changes every 6 months months)); Data Coordinating and Analysis Committee: Supervising data collection,management and quality control, designing the statistical analysis plan, performing unmasked data analysis and preparing interim and final reports for the Data Security Monitoring Board and the Executy Committee (Study Coordinator (Luis Rodriguez-Rodriguez), a representative from the Spanish Clinical Trial Network (Amanda López Picado) and Ester Carreño); Biobank and Biomarker Identification Committee (Maintaining an up-to-date manual of operations for blood extraction, processing and storage, and monitoring procedures adherence, supervising biological sample collection, sample shipment coordination, coordinating the phamacogenetic and proteomic analysis (Study Coordinator (Luis Rodriguez-Rodriguez), a representative from the Instituto de Salud Carlos III Biobank Platform (Elena Molino), a representative the Instituto de Investigación Biomédica de A Coruña, a representative from, the Data Coordinating and Analysis Committee); Data Security Monitoring Committee (PierGiogio Neri, Andrew Dick, Loreto Carmona

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

Mutational profiling using a custom 43-gene next-generation sequencing panel revealed that patients with mutated DNMT3A or EZH2, or an increase in TET2 VAF and lower TP53 VAF showed a higher overall response. NRAS and TP53 variants were associated with shorter overall survival (OS), whereas only mutated BCOR was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low-intermediate cytogenetic risk and mutated NRAS benefited from azacytidine therapy and patients with mutated TP53 showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML. We sought to predict treatment responses and outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group) based on mutational status, comparing azacytidine (AZA) with fludarabine plus low-dose cytarabine (FLUGA). Mutational profiling using a custom 43-gene next-generation sequencing panel revealed differences in profiles between older and younger patients, and several prognostic markers that were useful in young patients were ineffective in older patients. We examined the associations between variables and overall responses at the end of the third cycle. Patients with mutated DNMT3A or EZH2 were shown to benefit from azacytidine in the treatment-adjusted subgroup analysis. An analysis of the associations with tumor burden using variant allele frequency (VAF) quantification showed that a higher overall response was associated with an increase in TET2 VAF (odds ratio (OR), 1.014; p = 0.030) and lower TP53 VAF (OR, 0.981; p = 0.003). In the treatment-adjusted multivariate survival analyses, only the NRAS (hazard ratio (HR), 1.9, p = 0.005) and TP53 (HR, 2.6, p = 9.8 × 10 −7) variants were associated with shorter overall survival (OS), whereas only mutated BCOR (HR, 3.6, p = 0.0003) was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low-intermediate cytogenetic risk (HR, 1.51, p = 0.045) and mutated NRAS (HR, 3.66, p = 0.047) benefited from azacytidine therapy. In the subgroup analyses, patients with mutated TP53 (HR, 4.71, p = 0.009) showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML. The study is registered at ClinicalTrials.gov as NCT0231913

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

This study was supported by the Centro de Investigación Biomédica en Red—Área de Oncología—del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369; and CB16/12/00489), Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria (FIS No. PI13/02196), Asociación Española Contra el Cáncer (GCB120981SAN and the Accelerator Award), CRIS against Cancer foundation grant 2014/0120, and the Black Swan Research Initiative of the International Myeloma Foundation.Peer reviewe

Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

The screening of the BCR::ABL1 kinase domain (KD) mutation has become a routine analysis in case of warning/failure for chronic myeloid leukemia (CML) and B-cell precursor acute lymphoblastic leukemia (ALL) Philadelphia (Ph)-positive patients. In this study, we present a novel DNA-based next-generation sequencing (NGS) methodology for KD ABL1 mutation detection and monitoring with a 1.0E−4 sensitivity. This approach was validated with a well-stablished RNA-based nested NGS method. The correlation of both techniques for the quantification of ABL1 mutations was high (Pearson r = 0.858, p < 0.001), offering DNA-DeepNGS a sensitivity of 92% and specificity of 82%. The clinical impact was studied in a cohort of 129 patients (n = 67 for CML and n = 62 for B-ALL patients). A total of 162 samples (n = 86 CML and n = 76 B-ALL) were studied. Of them, 27 out of 86 harbored mutations (6 in warning and 21 in failure) for CML, and 13 out of 76 (2 diagnostic and 11 relapse samples) did in B-ALL patients. In addition, in four cases were detected mutation despite BCR::ABL1 < 1%. In conclusion, we were able to detect KD ABL1 mutations with a 1.0E−4 sensitivity by NGS using DNA as starting material even in patients with low levels of disease.Tis project was funded in part by CRIS CANCER FOUNDATION